(Reuters) -Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type 2 diabetes drug Mounjaro. Shares of the company rose 3.6 ...
Eli Lilly lifts 2024 sales view by $2 billion on weight-loss drug demand Updated / Tuesday, 30 Apr ... The drugmaker also raised its annual profit forecast by $1.30 per share to $13.50 to $14 per ...
US pharma major Eli Lilly (NYSE: LLY) today announced its financial results for the first quarter of 2024 and raised it guidance, with the news pushing the firm’s share up 5.6% to $778.19. Lilly ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
, opens new tab weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 5%. Lilly said it expects significant production ...
Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years ...